All stock lists
Oscar Health, Inc. (New York Stock Exchange:OSCR)
US · Delayed Price · Currency is USD
Healthcare · Medical - Healthcare Plans
30.91-0.08 (-0.26%)
Insider Score
––Not scored
OSCR Insider Score
Insiders filed in the last 90 days, but none of those trades qualified for scoring — round-trip buys and filings whose price is far off the market are excluded.
OSCR analyst forecast
OSCR analyst consensus
Hold7 ratings
Buy 2 Hold 4 Sell 1
Based on each firm’s most recent rating in the last 3 months — one vote per firm, so a desk that reiterates weekly does not count three times.
OSCR 12-month price target
$41.00+33.1% upsideaverage of 4 firms
$49.00High
$33.00Low
Best analysts covering OSCR
- Piper Sandler50%success rate · 4 calls
- Wells Fargo38%success rate · 8 calls
- B of A Securities17%success rate · 6 calls
- Barclays0%success rate · 1 call
Measured by us from each firm’s own rating dates and this stock’s split- and dividend-adjusted closes. How we calculate this.
OSCR analyst ratings
| Firm | Price target | Action | ||||
|---|---|---|---|---|---|---|
| — | UBS | Neutral | — | — | Reiterated | 2026-10-12 |
| — | Raymond James | Outperform | — | — | Reiterated | 2026-09-18 |
| — | Baird | Neutral | — | — | Reiterated | 2026-09-17 |
| — | B of A Securities | Underperform | — | — | Reiterated | 2026-09-17 |
| — | Stephens & Co. | Equal Weight | — | — | Reiterated | 2026-09-17 |
| Barclays | Overweight | $49.00 | +51.5% | Reiterated | 2026-09-17 | |
| Piper Sandler | — | $48.00 | +48.4% | — | 2026-09-17 | |
| Robert W. Baird | — | $33.00 | +2.0% | — | 2026-09-17 | |
| Goldman Sachs | — | $34.00 | +5.1% | — | 2026-09-17 | |
| — | Wells Fargo | Equal Weight | — | — | Reiterated | 2026-08-13 |
| — | UBS | Neutral | — | — | Reiterated | 2026-08-07 |
| — | Barclays | Overweight | — | — | Reiterated | 2026-08-07 |
| — | Barclays | Overweight | — | — | Upgraded | 2026-06-10 |
| — | Barclays | Equal Weight | — | — | Reiterated | 2026-05-26 |
| — | UBS | Neutral | — | — | Reiterated | 2026-05-07 |
| — | Baird | Neutral | — | — | Reiterated | 2026-05-07 |
| — | Barclays | Equal Weight | — | — | Reiterated | 2026-05-07 |
| — | Jefferies | Hold | — | — | Upgraded | 2026-04-20 |
| — | UBS | Neutral | — | — | Upgraded | 2026-01-09 |
| — | Barclays | Equal Weight | — | — | Upgraded | 2026-01-05 |
| — | Piper Sandler | Overweight | — | — | Upgraded | 2025-11-26 |
| — | Wells Fargo | Underweight | — | — | Reiterated | 2025-11-13 |
| — | Barclays | Underweight | — | — | Reiterated | 2025-11-10 |
| — | UBS | Sell | — | — | Reiterated | 2025-11-07 |
| — | Wells Fargo | Underweight | — | — | Reiterated | 2025-10-07 |
| — | Piper Sandler | Neutral | — | — | Reiterated | 2025-08-14 |
| — | Baird | Neutral | — | — | Downgraded | 2025-07-25 |
| — | Barclays | Underweight | — | — | Reiterated | 2025-07-23 |
| — | UBS | Sell | — | — | Downgraded | 2025-07-15 |
| — | Wells Fargo | Underweight | — | — | Downgraded | 2025-07-11 |
| — | Piper Sandler | Overweight | — | — | Reiterated | 2025-06-09 |
| — | Wells Fargo | Equal Weight | — | — | Downgraded | 2025-03-13 |
| — | B of A Securities | Underperform | — | — | Downgraded | 2024-11-06 |
| — | Piper Sandler | Overweight | — | — | Reiterated | 2024-09-10 |
| — | Piper Sandler | Overweight | — | — | Reiterated | 2024-08-08 |
| — | Piper Sandler | Overweight | — | — | Reiterated | 2024-07-10 |
| — | Wells Fargo | Overweight | — | — | Reiterated | 2024-06-12 |
| — | B of A Securities | Neutral | — | — | Downgraded | 2024-05-30 |
| — | B of A Securities | Buy | — | — | Reiterated | 2024-05-20 |
| — | Wells Fargo | Overweight | — | — | Reiterated | 2024-05-09 |
| — | Goldman Sachs | Neutral | — | — | Reiterated | 2024-05-09 |
| — | Wells Fargo | Overweight | — | — | Reiterated | 2024-02-15 |
| — | Goldman Sachs | Neutral | — | — | Reiterated | 2024-02-09 |
| — | B of A Securities | Buy | — | — | Reiterated | 2024-02-08 |
| — | B of A Securities | Buy | — | — | Upgraded | 2023-11-02 |
| — | Morgan Stanley | Equal Weight | — | — | Reiterated | 2023-08-30 |
| — | Goldman Sachs | Neutral | — | — | Reiterated | 2023-08-10 |
| — | Credit Suisse | Outperform | — | — | Reiterated | 2023-08-09 |
| — | Morgan Stanley | Equal Weight | — | — | Reiterated | 2023-07-14 |
| — | Wells Fargo | Overweight | — | — | Reiterated | 2023-06-13 |
| — | B of A Securities | Neutral | — | — | Upgraded | 2023-06-06 |
| — | Wells Fargo | Overweight | — | — | Reiterated | 2023-05-17 |
| — | Credit Suisse | Outperform | — | — | Reiterated | 2023-05-10 |
| — | B of A Securities | Underperform | — | — | Reiterated | 2023-03-29 |
| — | Goldman Sachs | Neutral | — | — | Reiterated | 2023-02-14 |
| — | Cowen & Co. | Market Perform | — | — | Reiterated | 2023-02-14 |
| — | Credit Suisse | Outperform | — | — | Reiterated | 2023-02-10 |
| — | Wells Fargo | Overweight | — | — | Upgraded | 2022-11-16 |
| — | Morgan Stanley | Equal Weight | — | — | Downgraded | 2022-11-14 |
| — | Morgan Stanley | Overweight | — | — | Reiterated | 2022-09-01 |
OSCR earnings vs. estimates
| Quarter | EPS est. | EPS actual | Revenue est. | Revenue actual |
|---|---|---|---|---|
| 2026-02-10 | -0.92 | -1.24 | $3.12B | $2.75B |
| 2026-05-06 | 1.21 | 2.07 | $4.89B | $4.58B |
| 2026-08-06 | 0.40 | 1.10 | $4.73B | $4.79B |
| 2026-11-05 | -0.14 | 0.00 | $4.69B | $0 |
Disclaimer — Informational only — not investment advice. Insider transaction data is sourced from SEC Form 4 filings; market data from public feeds and may be delayed. The Insider Score is a proprietary score for research purposes and does not predict future performance. Always do your own research.